HIGHLIGHTS

761   Selected Articles from This Issue

IN THE SPOTLIGHT

763   Choosing the Appropriate HPV Testing and Treatment Algorithm: What Works for Different Contexts?
Valerian Mwenda and Christine J. McGrath
See related article, p. 779

766   Prospective of Mitochondrial DNA Variations in Cancer on Genomic Medicine
Mulong Du
See related article by Chen and colleagues, Cancer Epidemiol Biomarkers Prev 2024;33:381–8

769   Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action
Bruna Pellini and Aadel A. Chaudhuri
See related article by Liu and colleagues, Cancer Epidemiol Biomarkers Prev 2024;33:489–99

MINIREVIEW

771   Inequities in the Impacts of Hurricanes and Other Extreme Weather Events for Cancer Survivors
Lisa M. Gudenkauf, Cassandra A. Hathaway, Judith E. Carroll, Brent J. Small, Xiaoyin Li, Aasha L. Hoogland, Eida Castro, Guillermo N. Armaiz-Pena, Laura B. Oswald, Heather S.L. Jim, Shelley S. Tworoger, and Brian D. Gonzalez

RESEARCH ARTICLES

779   Cervical Cancer Screening and Treatment Algorithms Using Human Papillomavirus Testing—Lessons Learnt from a South African Pilot Randomized Controlled Trial
Hannah M. Sebitloane, Mathilde Forestier, Themba G. Ginindza, Wendy Dhlomo, Eshia Moodley-Govender, Teresa M. Darragh, Armando Baena, Rolando Herrero, Maribel Almonte, Nathalie Broutet, and Hugo De Vuyst
See related In the Spotlight, p. 763

788   Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)

796   Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

804   Reproductive Factors Related to Childbearing and a Novel Automated Mammographic Measure, V

812   Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Jennifer A. Collister, Xiaolan Liu, Thomas J. Littlejohns, Jack Cuzick, Lei Clifton, and David J. Hunter

821   White Blood Cell Count, Neutrophil-to-Lymphocyte Ratio, and Incident Cancer in the UK Biobank
Minkyo Song, Barry I. Graubard, Erika Rottlieb, Charles S. Rabkin, and Eric A. Engels
TABLE OF CONTENTS

830 Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling
Jane M. Lange, Kemal Caglar Gogebakan, Roman Gulati, and Ruth Etzioni

838 Characterizing Cancer Burden in the American Indian Population in North Carolina
Lisa P. Spees, Bradford E. Jackson, Yadurshini Raveendran, Hayley N. Morris, Marc A. Emerson, Christopher D. Baggett, Ronny A. Bell, Ana I. Salas, Clare Meernik, Tomi F. Akinremi, and Stephanie B. Wheeler

846 Causal Relationship between Sex Hormone-Binding Globulin and Risk of Neuroblastoma: A Bidirectional Two-Sample Mendelian Randomization Study
Han Wu, Miao Ding, Jiabei Zhu, Siwei Mao, Xiaochen Tang, Sijia Fang, Li Liu, Qiuhi Pan, and Chaoyan Yue

854 Nitrosyl-heme and Heme Iron Intake from Processed Meats and Risk of Colorectal Cancer in the EPIC-Spain Cohort

857 Fine Particulate Matter, Noise Pollution, and Greenspace and Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort
Aleah L. Thomas, Jongeun Rhee, Jared A. Fisher, Marie-Josephe Horner, and Rena R. Jones

ABOUT THE COVER
The cover image is adapted from Fig. 1 in the article, “Causal Relationship between Sex Hormone-Binding Globulin and Risk of Neuroblastoma: A Bidirectional Two-Sample Mendelian Randomization Study,” Wu and Ding and colleagues. The causal relationship between sex hormone-binding globulin (SHBG) and neuroblastoma remains unknown. This study aimed to explore the causality between SHBG and the risk of neuroblastoma using bidirectional two-sample Mendelian randomization study. The study reveals that the elevated levels of male SHBG, but not female SHBG, significantly increase the risk of neuroblastoma positively, indicating that male SHBG plays a causal role in the incidence of neuroblastoma. Further research is needed to elucidate the underlying mechanisms of this gender disparity. Monitoring SHBG levels, especially in males, could be pivotal in neuroblastoma risk assessment and management. For more information, see the article beginning on page 846.

doi: 10.1158/1055-9965.EPI-33-6-CVR

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies/doi.